F-10: Eupraxia Pharmaceuticals Files for US$200 Million Shelf Prospectus, Aims for Nasdaq Listing

Eupraxia Pharmaceuticals files a preliminary short form base shelf prospectus for up to US$200 million in securities, seeking to list its common shares on the Nasdaq Capital Market.

Summary

• Eupraxia Pharmaceuticals Inc. has filed an amended and restated preliminary short form base shelf prospectus to offer up to US$200 million in common shares, preferred shares, debt securities, warrants, subscription receipts, and units.
• The securities may be offered separately or together, and may be issued for the acquisition of other businesses or assets.
• The company has applied to list its common shares on the Nasdaq Capital Market, subject to fulfilling listing requirements.
• Certain warrants of the company are already listed on the TSX under the symbols EPRX.WT and EPRX.WT.A.
• On January 17, 2024, the closing price of the Common Shares on the TSX was C$5.40, the closing price per warrant of the Listed Warrants with the trading symbol EPRX.WT was C$0.58, and the closing price per warrant of the Listed Warrants with the trading symbol EPRX.WT.A was C$3.50.
• The document highlights risks associated with investing in the securities, including the company's limited operating history, need for additional financing, and dependence on the success of its product candidates.
• Financial statements included or incorporated herein, if any, have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board, and may be subject to foreign auditing and auditor independence standards, and thus may not be comparable to financial statements of United States companies.

Sentiment

Score: 6

Explanation: The document is neutral in tone, primarily providing factual information about the company's plans and the terms of the offering. The inclusion of risk factors tempers any positive sentiment.

Positives

• The company is pursuing a Nasdaq listing, which could increase visibility and access to capital.
• The shelf prospectus provides flexibility for future financing and acquisitions.
• The company has warrants listed on the TSX.

Negatives

• The document emphasizes the speculative nature of the investment and associated risks.
• The company has a limited operating history and no products approved for commercial sale.
• The company will require substantial additional financing to achieve its goals.
• The company is substantially dependent on the success of its lead product candidate EP-104IAR.
• The company has a history of negative operating cash flow and may continue to experience negative operating cash flow.
• There is no established market for certain securities, and the Company does not know whether an active market will develop for Common Shares on the Nasdaq Capital Market if the Common Shares are listed.

Risks

• The company has a limited operating history and no products approved for commercial sale.
• The company will require substantial additional financing to achieve its goals.
• The company is substantially dependent on the success of its lead product candidate EP-104IAR.
• Clinical trials are expensive, time consuming and difficult to design and implement and may fail to demonstrate adequate safety and efficacy of our product candidates.
• Our current or future product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone or in combination with other products that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
• The market price of the Common Shares may be volatile.
• Our investors may lose their entire investment.

Future Outlook

The company intends to offer securities from time to time during the 25-month period that the prospectus remains effective.

Industry Context

The announcement is typical for a clinical-stage biotechnology company seeking capital to fund ongoing research and development activities. The pursuit of a Nasdaq listing is a common strategy to attract a broader investor base and potentially achieve a higher valuation.

Comparison to Industry Standards

• The document does not provide enough information to make a detailed comparison to industry standards.
• However, the company's strategy of developing locally delivered, extended-release alternatives to existing pharmaceuticals is aligned with current trends in drug development.
• Comparable companies pursuing similar strategies include Flexion Therapeutics (acquired by Pacira BioSciences), which developed Zilretta, an extended-release corticosteroid for osteoarthritis.

Stakeholder Impact

• Shareholders: Potential dilution from the issuance of new securities.
• Employees: No immediate impact, but future success depends on the company's ability to raise capital and advance its pipeline.
• Customers: No immediate impact, as the company has no approved products.
• Creditors: Potential impact on the company's debt obligations depending on the terms of any debt securities issued.

Next Steps

• The company will determine the specific terms of the securities offered in one or more prospectus supplements.
• The company will work to fulfill the listing requirements of the Nasdaq Capital Market.

Key Dates

Keywords

shelf prospectus, securities, Eupraxia Pharmaceuticals, Nasdaq, offering, EP-104IAR, common shares, warrants, debt